Stocktoria
Centessa Pharmaceuticals plc CNTA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-05-28
Centessa Pharmaceuticals plc statistics & valuation
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating margin | -1384.6% | — | -2499.4% | — | — | — |
| Net margin | -1316.9% | — | -2204.7% | — | — | — |
| FCF margin | -1294.6% | — | -2342.2% | — | — | — |
| Return on assets | -28.7% | -40.9% | -41.9% | -48.7% | -60.5% | -91.0% |
| Return on equity | -37.5% | -58.7% | -64.0% | -64.3% | -77.5% | — |
| Debt / equity | 0.21× | 0.27× | 0.32× | 0.21× | 0.15× | — |
| Current ratio | 8.57 | 9.25 | 8.00 | 11.42 | 25.52 | 1.30 |
Source: SEC EDGAR filings · CIK 0001847903 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.